EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease

Michael D Diamantidis iD, Georgia Ikonomou, Ioanna Argyrakouli, Despoina Pantelidou, Sophia Delicou iD, International Hemoglobinopathy Research Network (INHERENT)

International Journal of Molecular Sciences · 05.11.2024 · 25 (22) · 11886

DOI: 10.3390/ijms252211886 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2024. Verfasst von Michael D Diamantidis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Thalassemia and Sickle Cell Disease Unit, General Hospital of Larissa, 41221 Larissa, Greece. Hauptthemen laut MEDLINE: beta-Thalassemia, Anemia, Sickle Cell, Genetic Therapy, Hemoglobins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemoglobinopathies, namely β-thalassemia and sickle cell disease (SCD), are hereditary diseases, characterized by molecular genetic aberrations in the beta chains of hemoglobin. These defects affect the normal production of hemoglobin with severe anemia due to less or no amount of beta globins in patients with β-thalassemia (quantitative disorder), while SCD is a serious disease in which a mutated form of hemoglobin distorts the red blood cells into a crescent shape at low oxygen levels (qualitative disorder). Despite the revolutionary progress in recent years with the approval of gene therapy and gene editing for specific patients, there is an unmet need for highlighting the mechanisms influencing hemoglobin production and for the development of novel drugs and targeted therapies. The identification of the transcription factors and other genetic modifiers of hemoglobin expression is of utmost importance for discovering novel therapeutic approaches for patients with hemoglobinopathies. The aim of this review is to describe these complex molecular mechanisms and pathways affecting hemoglobin expression and to highlight the relevant investigational approaches or pharmaceutical interventions focusing on restoring the hemoglobin normal function by linking the molecular background of the disease with the clinical perspective. All the associated drugs increasing the hemoglobin expression in patients with hemoglobinopathies, along with gene therapy and gene editing, are also discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaAnemia, Sickle CellGenetic TherapyHemoglobinsHumansGene EditingHemoglobinopathiesbeta-GlobinsGene Expression RegulationGenes, Modifier

Stichwörter der Autor:innen

DNA methylationHbA2 (α2δ2)adult (α2β2) hemoglobin (HbA)fetal (α2γ2) hemoglobin (HbF)gene editinggene therapygenetic modifiershemoglobin expressionhemoglobinopathieshereditary persistence of fetal hemoglobin (HPFH)histone modificationhydroxyurea (HU)sickle cell disease (SCD)β-thalassemiaγ-globin gene expression

Substanzen

Hemoglobinsbeta-Globins

Autor:innen und Institutionen

  • Department of Hematology, Thalassemia and Sickle Cell Disease Unit, General Hospital of Larissa, 41221 Larissa, Greece.
  • Thalassemia and Sickle Cell Disease Prevention Unit, General Hospital of Larissa, 41221 Larissa, Greece.
  • Thalassemia and Sickle Cell Disease Unit, AHEPA University General Hospital, 41221 Thessaloniki, Greece.
  • Center of Expertise in Hemoglobinopathies and Their Complications, Thalassemia and Sickle Cell Disease Unit, Hippokration General Hospital, 41221 Athens, Greece.

ORCID-Profile: Michael D Diamantidis, Sophia Delicou

Zitieren

APA

Diamantidis, M. D., Ikonomou, G., Argyrakouli, I., Pantelidou, D., Delicou, S., & International Hemoglobinopathy Research Network (INHERENT) (2024). Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease. International Journal of Molecular Sciences, 25(22), 11886. https://doi.org/10.3390/ijms252211886

Vancouver

Diamantidis MD, Ikonomou G, Argyrakouli I, Pantelidou D, Delicou S, International Hemoglobinopathy Research Network (INHERENT). Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease. International Journal of Molecular Sciences. 2024;25(22):11886. doi:10.3390/ijms252211886

BibTeX
@article{Diamantidis2024,
  author = {Diamantidis, Michael D and Ikonomou, Georgia and Argyrakouli, Ioanna and Pantelidou, Despoina and Delicou, Sophia and International Hemoglobinopathy Research Network (INHERENT), International Hemoglobinopathy Research Network (INHERENT)},
  title = {Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {22},
  pages = {11886},
  doi = {10.3390/ijms252211886}
}
Kostenlos starten →